Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide, Abemaciclib, and Endocrinotherapy in HR+/HER2- Breast Cancer
NCT05464173Phase 2
Key facts
- Status
- Recruiting
- Start
- Jul 2022
- Primary completion
- Feb 2025
- Countries
- 1
- Drugs
- tucidinostat
- Conditions
- Hormone-Receptor-Positive Breast Cancer
01
Overview
Phase 2, open-label trial of tucidinostat in Hormone-Receptor-Positive Breast Cancer. Primary endpoint: Dose-Limiting Toxicity at 6 weeks. Started Jul 2022; status: recruiting.
02
Design
- Study design
- Non-randomizedOpen-labelSingle group
03
Who it enrols
Female patients with HR+/HER2- metastatic breast cancer who failed prior palbociclib therapy and have not received prior HDAC inhibitors or other CDK4/6 inhibitors.
04
Endpoints
Primary
Dose-Limiting Toxicity
Beyond the preview
Go deeper on NCT05464173.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05464173.